Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Retained Earnings (2016 - 2025)

PAVmed has reported Retained Earnings over the past 6 years, most recently at -$258.7 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 1.48% year-over-year to -$258.7 million; the TTM value through Dec 2025 reached -$258.7 million, down 1.48%, while the annual FY2025 figure was -$258.7 million, 1.48% down from the prior year.
  • Retained Earnings for Q4 2025 was -$258.7 million at PAVmed, down from -$256.9 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$97.8 million in Q1 2021 and troughed at -$320.6 million in Q2 2024.
  • A 5-year average of -$221.5 million and a median of -$246.2 million in 2023 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: tumbled 70.72% in 2022 and later increased 23.39% in 2025.
  • Year by year, Retained Earnings stood at -$138.9 million in 2021, then tumbled by 64.26% to -$228.2 million in 2022, then fell by 29.04% to -$294.4 million in 2023, then grew by 13.4% to -$255.0 million in 2024, then fell by 1.48% to -$258.7 million in 2025.
  • Business Quant data shows Retained Earnings for PAVM at -$258.7 million in Q4 2025, -$256.9 million in Q3 2025, and -$250.6 million in Q2 2025.